MedicReadT 3.0 Colon granted Canadian approval
24 September 2009 - 8:00AM
UK Regulatory
TIDMMDST
RNS Number : 5690Z
Medicsight Plc
24 September 2009
+------------------------------------+------------------------------------+
| Press Release | 24 September 2009 |
+------------------------------------+------------------------------------+
Medicsight Plc
("Medicsight" or "the Company")
MedicRead(TM) 3.0 Colon granted Canadian approval
Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, announces that it has received approval from the
Therapeutic Products Directorate (TPD) of Health Canada to market its
MedicRead(TM) 3.0 Colon advanced 3D visualisation workstation, incorporating
ColonCAD(TM) 4.0 software.
Previously, access to Medicsight's ColonCAD has been available via a number of
partner visualisation platforms. Now, as part of its ongoing commitment to
radiologists and to improving the early detection of colorectal cancers,
Medicsight has developed MedicRead 3.0 Colon, a competitively priced,
stand-alone, CTC visualisation workstation that incorporates the latest version
of Medicsight's ColonCAD 4.0. To aid access to this latest software, Medicsight
has made MedicRead 3.0 Colon available online, with a 30-day free trial version
of the software available via the Medicsight website (1).
Allan Rowley, Chief Executive of Medicsight, commented: "Canada is one of the
fastest growing multi-slice detector CT (MDCT) markets in the world. This
approval will give Medicsight direct access to the radiology departments in many
of the 450 hospitals and clinics across Canada and they can now benefit from the
Company's latest advances in CAD technology and CT image analysis software".
This year an estimated 22,000 Canadians (12,100 men - 9,900 women) will be
diagnosed with colorectal cancer (2). If diagnosed and treated in its early
stages, colorectal cancer is highly treatable. Routine screening tests that
detect polyps before they become cancerous can reduce the number of people who
die of colorectal cancer by as much as 60% (3).
Medicsight recently also received medical device licenses from the Therapeutic
Products Directorate of Health Canada for its MedicServer(TM) 1.1 application
which includes Medicsight's industry-leading ColonCAD(TM) 4.0 API and
LungCAD(TM) 3.2 API software. MedicServer(TM) is a unique server-based
Windows application, which has been specifically designed to optimise workflow
through centralised pre-processing of CT scan data.
Dr Tanya Chawla, Assistant Professor of Abdominal Imaging, Department of Imaging
at Mount Sinai Hospital, Toronto commented: "The approval of MedicRead 3.0 Colon
offers radiologists access to a cost effective CTC stand-alone workstation that
incorporates the latest version of ColonCAD. This is exciting because it
facilitates the performance of CT-colonography in radiology departments. It is
also an invaluable teaching tool and may be used as a second reader in the
appropriate setting."
ColonCAD 4.0 marks a significant increase in performance from the previous
version, displaying a 50% reduction in false positives without any significant
loss in sensitivity (4). This significantly enhances the contribution CAD can
make to workflow in busy radiology departments, compared with earlier versions.
Early detection of polyps can significantly improve chances of preventing
disease progression and Medicsight's CAD technology analyses CT scan data and
automatically highlights potential lesions for the radiologist to review. These
lesions could be the early precursors of potential life-threatening disease.
References
1. Subject to local regulatory approval.
2. Statistics Canada (www.statcan.gc.ca).
3. Smith RA, Mettlin CJ, Eyre H. 31. Cancer Screening and Early Detection. In:
D.W. Kufe et al., eds. Cancer Medicine. 6 ed. Hamilton, London: BC Decker Inc,
2003
4. Data on file Medicsight PLC 2009.
- ENDS -
For further information:
+-------------------------------------------+----------------------------+
| Medicsight PLC | www.medicsight.com |
+-------------------------------------------+----------------------------+
| Allan Rowley | +44 (0)20 7605 7950 |
| | |
+-------------------------------------------+----------------------------+
| Daniel Stewart & Company PLC | |
+-------------------------------------------+----------------------------+
| Simon Leathers | +44 (0) 20 7776 6550 |
+-------------------------------------------+----------------------------+
Media enquiries:
+-------------------------------------------+----------------------------+
| Abchurch | +44 (0) 20 7398 7700 |
+-------------------------------------------+----------------------------+
| Heather Salmond / Stephanie Cuthbert / | +44 (0) 20 7398 7718 |
| Simone Alves | |
+-------------------------------------------+----------------------------+
| stephanie.cuthbert@abchurch-group.com | www.abchurch-group.com |
+-------------------------------------------+----------------------------+
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung,
helping radiologists to identify, measure and analyse potential disease and
early indicators of disease. Medicsight's CAD software has been validated using
one of the world's largest and most population diverse databases of verified
patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLJMFTMMJTBBL
Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Medicsight (Londoner Börse): 0 Nachrichtenartikel
Weitere Medicsight News-Artikel